LUM and metabolic dysfunction-associated steatotic liver disease: This data suggests that lumican is expressed differentially across the progressive stages of NAFLD, indicating that this ECM component could be overexpressed at the beginning of the fibrogenic process in NAFLD patients with progressive disease.